Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Commercial services tags : Phase 2 save search
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
ALT | $7.075 0.5% 830K
|
Commercial Services
|
| O: 1.28%
H: 5.68%
C: -0.32%
obesity momentum positive topline trial results phase 2
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Published: 2023-09-12 (Crawled : 12:00) - globenewswire.com
ALT | $7.075 0.5% 830K
|
Commercial Services
|
| O: 0.82%
H: 7.76%
C: 6.53%
obesity momentum trial phase 2
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer
Published: 2023-05-09 (Crawled : 11:00) - globenewswire.com
ALXO | $15.35 -4.54% 160K
|
Commercial Services
|
| O: -2.94%
H: 10.25%
C: 9.58%
cancer trial phase 2
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
Published: 2023-04-11 (Crawled : 14:00) - biospace.com/
ALT | $7.075 0.5% 830K
|
Commercial Services
|
| O: -1.98%
H: 5.56%
C: 4.55%
hepatitis trial phase 2
Zentek Announces Successful Phase 2 Results of HVAC Testing
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
ZTEK | $1.14 1.33% 13K
|
Professional, Scientific, and T...
|
| O: 2.89%
H: 0.0%
C: -6.74%
IKTSY | $60.25 4.2K
|
Professional, Scientific, and T...
|
| O: -1.86%
H: 0.0%
C: -0.96%
results phase 2
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Published: 2022-09-28 (Crawled : 12:00) - globenewswire.com
ALT | $7.075 0.5% 830K
|
Commercial Services
|
| O: 0.08%
H: 15.69%
C: 13.15%
obesity trial momentum phase 2
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
LLY | News | $749.39 -0.18% 350K
|
Health Technology
|
| O: -1.18%
H: 1.46%
C: 0.05%
ALXO | $15.35 -4.54% 160K
|
Commercial Services
|
| O: 2.97%
H: 6.15%
C: -1.44%
trial cancer phase 2
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
Published: 2022-04-01 (Crawled : 21:00) - biospace.com/
ALT | $7.075 0.5% 830K
|
Commercial Services
|
| O: 0.0%
H: 4.8%
C: 2.13%
obesity trial phase 2
GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials
Published: 2022-03-14 (Crawled : 13:30) - biospace.com/
RSSS 4 | $3.02 -1.31% 2.7K
|
Commercial Services
|
| O: 1.07%
H: 1.71%
C: 1.25%
GOVX | $1.62 10.96% 9.7K
|
Health Technology
|
| O: 0.0%
H: 1.35%
C: -4.73%
covid-19 phase 2 als trials trial covid clinical trials vaccine
UK Competition and Markets Authority to Refer Ritchie Bros.' Proposed Acquisition of Euro Auctions for Phase 2 Review
Published: 2022-03-04 (Crawled : 14:30) - prnewswire.com
RBA | $73.25 0.06% 12K
|
Commercial Services
|
| O: -0.48%
H: 0.0%
C: 0.0%
phase 2 acquisition pos
ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction CancerPhase 2/3 study initiated in collaboration with Eli Lilly and Company
Published: 2022-03-02 (Crawled : 18:00) - biospace.com/
LLY | News | $749.39 -0.18% 350K
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALXO | $15.35 -4.54% 160K
|
Commercial Services
|
| O: 0.0%
H: 4.13%
C: 3.97%
aspen-06 treatment phase 2 phase 2/3 collaboration cancer initiated
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for ObesityEnrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022
Published: 2022-01-31 (Crawled : 15:00) - biospace.com/
ALT | $7.075 0.5% 830K
|
Commercial Services
|
| O: 2.92%
H: 9.31%
C: 8.91%
alt-801 fda obesity phase 2 clearance trial fda clearance
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
Published: 2021-12-29 (Crawled : 14:00) - biospace.com/
SLRX A | $0.5105 380
|
Commercial Services
|
| O: -2.86%
H: 5.69%
C: -3.43%
als ongoing trial phase 1 phase 2 milestone phase 3
S&P Global and IHS Markit Update on Pending Merger Following CMA's Phase 1 Findings
Published: 2021-10-19 (Crawled : 12:00) - prnewswire.com
SPGI | $414.0 0.46% 140K
|
Commercial Services
|
| O: 0.46%
H: 0.72%
C: 0.26%
phase 1 merge phase 3 phase 2
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
ALT | $7.075 0.5% 830K
|
Commercial Services
|
| O: -28.7%
H: 39.15%
C: 36.75%
positive results phase 1 positive results trial obesity phase 2 phase 3
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Published: 2021-09-27 (Crawled : 23:00) - globenewswire.com
ALT | $7.075 0.5% 830K
|
Commercial Services
|
| O: -28.7%
H: 39.15%
C: 36.75%
phase 1 trial phase 2 phase 3
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
Published: 2021-07-28 (Crawled : 12:00) - biospace.com/
ALXO | $15.35 -4.54% 160K
|
Commercial Services
|
| O: -0.94%
H: 4.37%
C: 4.28%
treatment phase 2 therapy keytruda agx148 cell carcinoma
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
ALT | $7.075 0.5% 830K
|
Commercial Services
|
| O: 2.19%
H: 34.76%
C: 13.99%
phase 1 positive trial phase 3 phase 2 obesity
ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies
Published: 2021-06-14 (Crawled : 12:00) - biospace.com/
ALXO | $15.35 -4.54% 160K
|
Commercial Services
|
| O: 0.69%
H: 4.2%
C: 0.17%
phase 2 cancer agx148
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
Published: 2021-05-10 (Crawled : 12:00) - biospace.com/
ALXO | $15.35 -4.54% 160K
|
Commercial Services
|
| O: -0.65%
H: 0.0%
C: -4.41%
treatment phase 2 keytruda agx148 cell carcinoma
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
SINT | $0.0588 57.64% 240M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.